NP001: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects with Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation

Grants and Contracts Details

StatusFinished
Effective start/end date9/12/169/11/18

Funding

  • Neuraltus Pharmaceuticals Incorporated: $148,811.00